HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Status:
Recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine whether the combination of imaging agents 68-Ga
RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy
than standard imaging or biopsy in patients with known prostate cancer (PC)